(3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine | 197900-77-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine
• 英文别名: (-)-4-phenyl-piperidine-1,3-dicarboxylic acid-1-tert-butyl ester；1-tert-butyl ester (3S,4S)-4-phenyl-piperidine-1,3-dicarboxylate；(3S,4S)-4-phenyl-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester；(3S,4S)-1-(tert-Butoxycarbonyl)-4-phenylpiperidine 3-carboxylic acid；(3S,4S)-1-(tert-Butoxycarbonyl)-4-phenylpiperidine-3-carboxylic acid；(3S,4S)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylpiperidine-3-carboxylic acid
• CAS: 197900-77-9
• 化学式: C₁₇H₂₃NO₄
• 分子量: 305.374
• InChiKey: UHRXHCZPUWORFZ-ZIAGYGMSSA-N

物化性质

• 沸点：
  454.9±45.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine 在 N-甲基吗啉 、 甲醇 、 sodium 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 生成 (3R,4S)-3-{(R)-3-[6-(4-Chloro-phenylsulfanyl)-2-(4-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazin-4-yl]-1-methyl-propylcarbamoyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Design and syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype

  摘要：

  The discovery and optimization of a new class of non-peptidyl, pyridazinone derived melanocortin subtype-4 receptor agonists is disclosed. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.026
• 作为产物：
  描述：

  三甲基(苯基)锡 在 palladium on activated charcoal N-甲基吡咯烷酮 、 palladium diacetate 、 lithium hydroxide 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 生成 (3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine
  参考文献：
  名称：

  Selective α-1A adrenergic receptor antagonists. effects of pharmacophore regio- and stereochemistry on potency and selectivity

  摘要：

  The anti-anxiety agent ipsapirone has been shown to have modest affinity for alpha-1 receptors. We disclose the discovery of potent alpha-1a receptor subtype selective antagonists based on the ipsapirone structure which possess selectivity versus the 5-HT receptors tested. These antagonists were obtained by tethering a saccharin ring to 4-phenyl-3-carboxyethyl piperidines. The design principles which led to this structural motif are discussed. The synthesis of key analogs, their SAR, as well as results of selected in vitro and in vivo studies are described. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00451-x
• 作为试剂：
  描述：

  (3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine 、 (3S,4S)-3-[4-(2,5-dimethyl-phenyl)-piperazine-1-carbonyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 在 (3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine 作用下， 生成 1-(2,5-二甲基苯基)哌嗪
  参考文献：
  名称：

  Piperazine amide derivatives

  摘要：

  这项发明涉及公式(I)中的新型哌嗪酰胺衍生物，其中R1至R11、W、X和Y如说明书和权利要求中所定义，以及其生理学上可接受的盐。这些化合物与LXR alpha和LXR beta结合，可用作药物。

  公开号：

  US08288541B2

文献信息

• NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20160221948A1

  公开（公告）日：2016-08-04

  The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R 1 represents optionally substituted C 1-4 alkyl, n shows integer of 1 to 4, R 2 represents optionally substituted C 1-4 alkyl or hydrogen atom, R 3 represents optionally substituted C 1-4 alkyl, R 4a , R 4b , R 4c , and R 4d , similarly or differently, represent optionally substituted C 6-14 aryl, optionally substituted C 1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C 6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

  本发明提供了一种由下式(I)表示的化合物或其药用可接受的盐： [其中，R1表示可选地取代的C1-4烷基，n表示1到4的整数，R2表示可选地取代的C1-4烷基或氢原子，R3表示可选地取代的C1-4烷基，R4a、R4b、R4c和R4d，相同或不同，表示可选地取代的C6-14芳基，可选地取代的C1-4烷基，或氢原子等，A表示可选地取代的C6-14芳基或可选地取代的5至11成员的杂芳基]。
• PIPERAZINE AMIDE DERIVATIVES
  申请人：Dehmlow Henrietta

  公开号：US20090048264A1

  公开（公告）日：2009-02-19

  The invention is concerned with novel piperazine amide derivatives of formula (I) wherein R 1 to R 11 , W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

  这项发明涉及一种新型哌嗪酰胺衍生物，其化学式为（I），其中R1至R11、W、X和Y如描述和索赔中定义，并且其生理上可接受的盐。这些化合物能够结合到LXRα和LXRβ，并可用作药物。
• Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety
  申请人：Grundschober Christophe

  公开号：US20070232652A1

  公开（公告）日：2007-10-04

  The present invention relates to trans-derivatives of formula wherein R 1 , R 2 , R 3 , and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.

  本发明涉及公式中的转衍生物，其中R1、R2、R3和虚线如本文所定义，并且其药用可接受酸盐。公式I的化合物是良好的5-羟色胺转运体抑制剂（SERT抑制剂），同时它们对NK-1受体也具有良好的活性（双重效应）。由于其作为SERT抑制剂的功效，本发明中的化合物特别适用于治疗中枢神经系统疾病和精神疾病，特别是在治疗或预防抑郁状态和/或焦虑症的治疗中。
• Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids
  申请人：Bachmann Stephan

  公开号：US20070232653A1

  公开（公告）日：2007-10-04

  The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined herein and corresponding salts thereof.

  本发明涉及一种通过对下列方案进行对映选择性氢化反应，制备高对映异构体和对映选择性的顺式取代的环状β-芳基或杂芳基羧酸衍生物的方法，其中X、Ar、n和m在此定义，并且包括相应的盐。
• BICYCLIC HETEROCYCLIC DERIVATIVE
  申请人：Nakahira Hiroyuki

  公开号：US20110190278A1

  公开（公告）日：2011-08-04

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R 1a is halogen, etc.; R 1m is H, etc.; G 1 is —N(R 1b )—, etc.; G 2 is —CO—, etc.; G 3 is —C(R 1c )(R 1d )—, etc.; G 4 is oxygen, etc.; R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are independently the same or different, H, etc.; R 3 is H, optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3 c and R 3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]